Induced second trimester abortion by extra-amniotic prostaglandin infusion in patients with a cesarean scar: is it safe?
BACKGROUND
One result of the advancement in prenatal diagnosis is an increase in the need for second trimester pregnancy terminations. Extra-amniotic infusion of prostaglandins is a common technique used for such pregnancy termination. Since prostaglandins cause strong uterine contractions, many practitioners are hesitant to use this technique on women with a uterine scar. In this study we tried to evaluate the effectiveness and safety of the technique for women with a previous uterine scar.


METHODS
This retrospective study included all women with a complete medical record who underwent a second trimester pregnancy termination at our institution by extra amniotic prostaglandin E2, during a 6 year period. The study group included all women with a previous uterine scar. The group of women without such a scar served as the control group.


RESULTS
Three hundred and forty women had their pregnancy terminated, but only in 282 cases was the medical information complete (research population). The study group (35 women) characteristics were similar to those of the control group (247 women). We found no difference in the abortion interval, the need to use an additional method, the need for curettage and in bleeding complication between the two groups. There was no case of uterine rupture. The group of women with multiple uterine scars was too small for analysis.


CONCLUSIONS
Our results suggest that extra amniotic prostaglandin infusion is an effective and safe technique in women with a uterine scar.
Shapira
S
S
Department of Obstetrics and Gynecology, Meir Hospital, Kfar-Saba, Israel.
Goldberger
S
S
Beyth
Y
Y
Fejgin
M D
MD
D000019:Abortifacient Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000028:Abortion, Induced / Q000009:adverse effects / Q000379:methods*; D000293:Adolescent; D000328:Adult; D002585:Cesarean Section; D002921:Cicatrix / Q000209:etiology; D015232:Dinoprostone / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008423:Maternal Age; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D012189:Retrospective Studies
D000019:Abortifacient Agents; D015232:Dinoprostone